

Pharma code area

Pharma code area

LM36905–LE001

Package leaflet: Information for the user

Herzuma[®] 420 mg

Powder for concentrate for solution for infusion

trastuzumab

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- What Herzuma is and what it is used for
- What you need to know before you use Herzuma
- How to use Herzuma
- Possible side effects
- How to store Herzuma
- Contents of the pack and other information

1. What Herzuma is and what it is used for

Herzuma contains the active substance trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Herzuma binds to HER2 it stops the growth of such cells and causes them to die.

Your doctor may prescribe Herzuma for the treatment of breast and gastric cancer when:

- you have early breast cancer, with high levels of a protein called HER2.
- you have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. Herzuma may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).
- you have metastatic gastric cancer with high levels of HER2, when it is in combination with the other cancer medicines capecitabine or 5-fluorouracil and cisplatin.

2. What you need to know before you use Herzuma

Do not take Herzuma if:

- you are allergic to trastuzumab, to murine (mouse) proteins or any of the other ingredients of this medicine (listed in section 6).
- you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.

Warnings and precautions

Your doctor will closely supervise your therapy.

Heart checks

Treatment with Herzuma alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer). The effects may be moderate to severe and could cause death. Therefore, your heart function will be checked before, during (every three months) and after (up to two to five years) treatment with Herzuma. If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Herzuma treatment.

Talk to your doctor, pharmacist or nurse before you are given Herzuma if:

- you have had heart failure, coronary artery disease, heart valve disease (heart murmurs), high blood pressure, taken any high blood pressure medicine or are currently taking any high blood pressure medicine.
- you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with trastuzumab.
- you suffer from breathlessness, especially if you are currently using a taxane. Trastuzumab can cause breathing difficulties, especially when it is first given. This could be more serious if you are already breathless. Very rarely, patients with severe breathing difficulties before treatment have died when they were given trastuzumab.
- you have ever had any other treatment for cancer.

If you receive Herzuma with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read the patient information leaflets for these products.

Children and adolescents

Herzuma is not recommended for anyone under the age of 18 years.

Other medicines and Herzuma

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or may take any other medicines.

The following information is intended for medical or healthcare professionals only

Always keep this medicine in the closed original pack at a temperature of 2°C – 8°C in a refrigerator. A vial of Herzuma reconstituted with water for injections (not supplied) is stable for 7 days at 2°C – 8°C after reconstitution and must not be frozen.

Appropriate aseptic technique should be used. Each vial of Herzuma is reconstituted with 20 mL of water for injections (not supplied). Use of other reconstitution solvents should be avoided. The reconstituted solution contains approximately 21 mg/mL trastuzumab and delivers 20 mL (420 mg trastuzumab) solution for single-dose use. A volume overage of 4 % ensures that the labelled dose of 420 mg can be withdrawn from each vial.

Herzuma should be carefully handled during reconstitution. Causing excessive foaming during reconstitution or shaking the reconstituted Herzuma may result in problems with the amount of Herzuma that can be withdrawn from the vial.

It may take up to 7 months for Herzuma to be removed from the body. Therefore you should tell your doctor, pharmacist or nurse that you have had Herzuma if you start any new medicine in the 7 months after stopping treatment.

Pregnancy

- If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.
- You should use effective contraception during treatment with Herzuma and for at least 7 months after treatment has ended.
- Your doctor will advise you of the risks and benefits of taking Herzuma during pregnancy. In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving Herzuma. This condition may be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in foetal death.

Breast-feeding

Do not breast-feed your baby during Herzuma therapy and for 7 months after the last dose of Herzuma as Herzuma may pass to your baby through your breast milk.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

Herzuma may affect your ability to drive a car or operate machines. If during treatment you experience symptoms, such as chills or fever, you should not drive or use machines until these symptoms disappear.

3. How to use Herzuma

Before starting the treatment your doctor will determine the amount of HER2 in your tumour. Only patients with a large amount of HER2 will be treated with Herzuma. Herzuma should only be given by a doctor or nurse. Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Herzuma depends on your body weight.

Herzuma is given as an intravenous infusion (“drip”) directly into your veins. The first dose of your treatment is given over 90 minutes and you will be observed by a health professional while it is being given in case you have any side effects. If the first dose is well tolerated the next doses may be given over 30 minutes (see section 2 under “Warnings and precautions”). The number of infusions you receive will depend on how you respond to the treatment. Your doctor will discuss this with you.

In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is Herzuma (trastuzumab) and not trastuzumab emtansine.

For early breast cancer, metastatic breast cancer and metastatic gastric cancer, Herzuma is given every 3 weeks. Herzuma may also be given once a week for metastatic breast cancer.

If you stop using Herzuma

Do not stop using this medicine without talking to your doctor first. All doses should be taken at the right time every week or every three weeks (depending on your dosing schedule). This helps your medicine work as well as it can.

It may take up to 7 months for Herzuma to be removed from your body. Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects may be serious and may lead to hospitalisation.

During a Herzuma infusion, chills, fever and other flu like symptoms may occur. These are very common (may affect more than 1 in 10 people). Other infusion-related symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, wheezing, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired. Some of these symptoms can be serious and some patients have died (see section 2 under “Warnings and precautions”).

These effects mainly occur with the first intravenous infusion (“drip” into your vein) and during the first few hours after the start of the infusion. They are usually temporary. You will be observed by a health care professional during the infusion and for at least six hours after the start of the first infusion and for two hours after the start of other infusions. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.

Occasionally, symptoms start later than six hours after the infusion begins. If this happens to you, contact your doctor immediately. Sometimes, symptoms may improve and then get worse later.

Other side effects can occur at any time during treatment with Herzuma, not just related to an infusion. Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. They include weakening of the heart muscle possibly leading to heart failure, inflammation (swollen, red, hot, and in pain) of the lining around the heart and heart rhythm disturbances. This can lead to symptoms such as:

- breathlessness (including breathlessness at night),
- cough,
- fluid retention (swelling) in the legs or arms,
- palpitations (heart fluttering or irregular heart beat).

Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms.

If you experience any of the above symptoms when your treatment with Herzuma has finished, you should see your doctor and tell them that you have previously been treated with Herzuma.

Very common side effects (may affect more than 1 in 10 people):

- infections
- diarrhoea
- constipation

Instruction for reconstitution and dilution:

1) Using a sterile syringe, slowly inject 20 mL of water for injections in the vial containing the lyophilised Herzuma, directing the stream into the lyophilised cake.

2) Swirl vial gently to aid reconstitution. DO NOT SHAKE!

Slight foaming of the product upon reconstitution is not unusual. Allow the vial to stand undisturbed for approximately 5 minutes. The reconstituted Herzuma results in a colourless to pale yellow transparent solution and should be essentially free of visible particulates.

Determine the volume of the solution required:

- based on a loading dose of 4 mg trastuzumab/kg body weight, or a subsequent weekly dose of 2 mg trastuzumab/kg body weight:

Volume (mL) =

Body weight (kg)
×
dose

(4
mg/kg
for
loading
or
2
mg/kg
for
maintenance)

21
(mg/mL,
concentration
of
reconstituted
solution)

- heartburn (dyspepsia)
- weakness
- skin rashes
- chest pain
- abdominal pain
- joint pain
- low counts of red blood cells and white blood cells (which help fight infection) sometimes with fever
- muscle pain
- conjunctivitis
- watery eyes
- nose bleeds
- runny nose
- hair loss
- tremor
- hot flush
- dizziness
- nail disorders
- weight loss
- loss of appetite
- inability to sleep (insomnia)
- altered taste
- low platelet count
- bruising
- numbness or tingling of the fingers and toes
- redness, swelling or sores in your mouth and/or throat
- pain, swelling, redness or tingling of hands and/or feet
- breathlessness
- headache
- cough
- vomiting
- nausea

Common side effects (may affect up to 1 in 10 people):

- allergic reactions
- throat infections
- bladder and skin infections
- shingles
- inflammation of the breast
- inflammation of the liver
- kidney disorders
- increased muscle tone or tension (hypertonia)

- pain in the arms and/or legs
- itchy rash
- sleepiness (somniaence)
- haemorrhoids
- itchiness
- dry mouth and skin
- dry eyes
- sweating
- feeling weak and unwell
- anxiety
- depression
- abnormal thinking
- asthma
- infection of lungs
- lung disorders
- back pain
- neck pain
- bone pain
- acne
- leg cramps

Uncommon side effects (may affect up to 1 in 100 people):

- deafness
- bumpy rash
- blood infection

Rare side effects (may affect up to 1 in 1000 people):

- weakness
- jaundice
- inflammation or scarring of the lungs

Other side effects that have been reported with Herzuma use (frequency cannot be estimated from the available data):

- abnormal or impaired blood clotting
- anaphylactic reactions
- high potassium levels
- swelling of the brain
- swelling or bleeding at the back of the eyes
- shock
- swelling of the lining of the heart
- slow heart rate
- abnormal heart rhythm
- respiratory distress
- respiratory failure
- acute accumulation of fluid in the lungs

- based on a loading dose of 8 mg trastuzumab/kg body weight, or a subsequent 3-weekly dose of 6 mg trastuzumab/kg body weight:

Volume (mL) =

Body weight (kg)
×
dose

(8
mg/kg
for
loading
or
6
mg/kg
for
maintenance)

21
(mg/mL,
concentration
of
reconstituted
solution)

The appropriate amount of solution should be withdrawn from the vial and added to a polyvinylchloride, polyethylene or polypropylene infusion bag containing 250 mL of 0.9 % sodium chloride solution. Do not use with glucose-containing solutions. The bag should be gently inverted to mix the solution in order to avoid foaming. Parenteral solutions should be inspected visually for particulates and discoloration prior to administration. Once the infusion is prepared it should be administered immediately. If diluted aseptically, it may be stored for 24 hours (do not store above 30°C).

- acute narrowing of the airways
- abnormally low oxygen levels in the blood
- difficulty in breathing when lying flat
- liver damage/failure
- swelling of the face, lips and throat
- kidney failure
- abnormally low levels of fluid around baby in womb
- failure of the lungs of the baby to develop in the womb
- abnormal development of the kidneys of the baby in the womb

Some of the side effects you experience may be due to your underlying cancer. If you receive Herzuma in combination with chemotherapy, some of them may also be due to the chemotherapy.

If you get any side effects, talk to your doctor, pharmacist or nurse.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via UK: Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Herzuma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the on the outer carton and on the vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

Infusion solutions should be used immediately after dilution. Do not use Herzuma if you notice any particulate matter or discoloration prior to administration.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Herzuma contains

- The active substance is trastuzumab. Each vial contains 420 mg trastuzumab that has to be dissolved in 20 mL of water for injection. The resulting solution contains approximately 21 mg/mL trastuzumab.
- The other ingredients are L-histidine hydrochloride, L-histidine, α,α -trehalose dihydrate, polysorbate 20.

What Herzuma looks like and contents of the pack

Herzuma is a powder for concentrate for solution for intravenous infusion, which is supplied in a glass vial with a rubber stopper containing 420 mg of trastuzumab. The powder is a white to pale yellow pellet. Each carton contains 1 vial of powder.

Marketing Authorisation Holder

Celltrion Healthcare Hungary Kft.
1062 Budapest, Váci út 1-3.
WestEnd Office Building B torony.
Hungary

Manufacturer

Biotec Services International Ltd.
Biotec House
Central Park
Western Avenue
Bridgend Industrial Estate
Bridgend, CF31 3RT
United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom

NAPP Pharmaceuticals Ltd.
Tel: +44-(0)-1223-424444

This leaflet was last revised in March 2019.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: <http://www.ema.europa.eu>

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line on:

United Kingdom 0800 198 5000

You will need to give details of the product name and reference number.

These are as follows:

Product name: **Hermuza**

Reference number: EU/1/17/1257/002